Sutro: Encouraging Interim Data on Phase 1 Ovarian Cancer Study

 Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels-including 1 CR, 3 cPRs and 6 uPRs -

- Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment -

- Dose-expansion has been initiated to explore 4.3 & 5.2 mg/kg in less heavily pre-treated patient population -

To access the live virtual event on Thursday, Dec. 3, at 2pm PT (5pm ET), please click here. An archived webcast of the event will be available on the Investor section of the company's website at ir.sutrobio.com for approximately 30 days.

https://finance.yahoo.com/news/sutro-biopharma-announces-encouraging-interim-213000411.html